-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 E12cIF45C8G3h4G3emjUoMyyam0JPszZUAogGBXEAQKnYp9FkNpNi5vFG0i4cDzb
 arEsP83svd6TtiWp7m70cg==

<SEC-DOCUMENT>0001075880-08-000073.txt : 20081029
<SEC-HEADER>0001075880-08-000073.hdr.sgml : 20081029
<ACCEPTANCE-DATETIME>20081029065858
ACCESSION NUMBER:		0001075880-08-000073
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20081029
FILED AS OF DATE:		20081029
DATE AS OF CHANGE:		20081029

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		081146161

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k20081029.htm
<DESCRIPTION>FORM 6K 2008 10 29
<TEXT>
<html>
  <head>
    <title>form6k20081029.htm</title>
<!-- Licensed to: Novogen Laboratories Pty Ltd-->
<!-- Document Created using EDGARizer 4.0.6.3 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; MARGIN-LEFT: 5%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5%; FONT-FAMILY: Times New Roman">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 26pt; FONT-FAMILY: Times New Roman, serif">UNITED
STATES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 26pt; FONT-FAMILY: Times New Roman, serif">SECURITIES
AND EXCHANGE COMMISSION</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Washington,
D.C. 20549</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">______________________________________________</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Form
6-K</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">SECURITIES
EXCHANGE ACT OF 1934</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">For the
month of October, 2008</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Commission
File Number <font style="DISPLAY: inline; FONT-FAMILY: Times New Roman">________________</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 26pt; FONT-FAMILY: Times New Roman, serif">Novogen
Limited</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">(Translation
of registrant&#8217;s name into English)</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">140 Wicks
Road, North Ryde, NSW, Australia</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">(Address
of principal executive office)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">___________________________________</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Form 20-F
<font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">x</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>Form 40-F <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l):<font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font><font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security
holders.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7): <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
which the registrant&#8217;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant&#8217;s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">o</font><font style="DISPLAY: inline; FONT-WEIGHT: bold">&#160;</font>No <font style="DISPLAY: inline; FONT-WEIGHT: bold;" face="Wingdings">x</font></font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">If &#8220;Yes&#8221;
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):</font></div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf </font>by the undersigned, thereunto duly
authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Novogen
Limited</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">(Registrant)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">/s/&#160;&#160;Ron
Erratt</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Ronald
Lea Erratt</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Company
Secretary</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="justify"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Date
29 October, 2008</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right" align="justify">&#160;</div>
    <div style="TEXT-ALIGN: right">
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: right">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: right">&#160;</div>
    <div style="DISPLAY: block; TEXT-INDENT: 0pt; TEXT-ALIGN: right"><br>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="TEXT-ALIGN: right">&#160;</div>
    <div style="TEXT-ALIGN: right">&#160;</div>
    <div style="TEXT-ALIGN: right">&#160;</div>
    <div style="TEXT-ALIGN: right"><img src="novogenletterhead.jpg" alt="Novogen Logo"></div>
    <div style="TEXT-ALIGN: right">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">ASX
&amp; MEDIA RELEASE</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">29
OCTOBER, 2008</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">MARSHALL
EDWARDS&#8217; PHENOXODIOL AND NOVOGEN&#8217;S NV-128&#160;&#160;DISPLAY DIVERGENT
MECHANISMS OF ACTION BUT POTENT SYNERGISTIC ANTI-CANCER ACTIVITY WHEN USED IN
COMBINATION</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Pre-clinical
studies presented at the 9th International Conference on Membrane Redox Systems
in Wellington New Zealand this week demonstrate that Novogen&#8217;s NV-128 (a novel
mTOR inhibitor), when used in combination with the Marshall Edwards, Inc&#8217;s.
Phase&#160;III anti-ovarian cancer drug, phenoxodiol, produces potent
synergistic anti-cancer activity against non-small cell lung carcinoma cell
lines (NSCLC).&#160;&#160;Importantly, the synergistic cytotoxicity observed
between NV-128 and phenoxodiol was superior to the synergy observed between
NV-128 and paclitaxel against NSCLC.&#160;&#160;These data were presented by Dr
David Brown, Program Manager (Cancer Biology), Novogen.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">&#8220;In NSCLC
targets, these two drugs in combination produced an anti-cancer effect superior
to that achieved with either drug alone or in combination with current approved
anti-cancer cytotoxic drugs.&#160;&#160;The potential for improved efficacy,
coupled with the safety profile of these novel drugs, suggests the potential for
clinical benefits in lung cancer patients which cannot be achieved with current
standard of care drugs,&#8221; Dr Brown said.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Phenoxodiol
is being developed as a therapy for late-stage, chemoresistant prostate and
ovarian cancers.&#160;&#160;It is a novel-acting drug that inhibits key
pro-survival signalling pathways operating via sphingosine-1-phosphate and
Akt.&#160;&#160;Inhibition of these pathways leads to prevention of
phosphorylation of key anti-apoptotic proteins such as XIAP and
FLIPs.&#160;&#160;Loss of activity of these proteins restores the ability of
chemoresistant tumour cells to undergo caspase-mediated apoptosis in response to
chemotherapy.&#160;&#160;The putative molecular target for phenoxodiol is a
surface oxidase which is preferentially expressed on cancer cells and is linked
to the expression of pro-survival pathways in these cells.&#160;&#160;The
ability of the drug to bind preferentially to cancer cells rather than normal
cells is reflected in its high safety profile in clinical use.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">In
contrast to phenoxodiol, NV-128 does not induce caspase-mediated apoptosis, a
death mechanism which is often non-functional in chemoresistant cancer cells due
to accumulated mutations in tumour suppressor/promoter genes and over-expression
of anti-apoptotic proteins.&#160;&#160;Rather, NV-128 uncouples the
akt-mTOR&#173;-P70S6K signal transduction cascade which has a key role in driving
protein translation and uncontrolled cancer cell
proliferation.&#160;&#160;Further, NV-128 induces mitochondrial depolarisation
via a novel pathway involving the autophagy protein Beclin-1 and Bcl-2, thereby
resulting in endonuclease G translocation to the nucleus and cell
death.&#160;&#160;Importantly, when NV-128 is used in combination with
phenoxodiol, XIAP is degraded in these cells allowing the caspase-mediated
apoptosis cascade to be engaged in addition to NV-128-endonuclease G mediated
apoptosis resulting in two pathways to cell death.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">&#8220;These
data provide direct evidence that while invoking discrete modes of cell death,
NV-128 and phenoxodiol can be used synergistically to force the convergence of
caspase-mediated and caspase-independent cell death pathways to drive overall
cell death&#8221;, said Dr Brown.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">About
Novogen Limited:</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Novogen
Limited (ASX: NRT; NASDAQ: NVGN) is an Australian biotechnology company that has
patented isoflavone technology for the treatment and prevention of degenerative
diseases and disorders.&#160;&#160;Over the past ten years, Novogen has
conducted the largest and most comprehensive isoflavone clinical testing
programs in the world.&#160;&#160;Novogen is involved in drug discovery and
product development for a range of degenerative disorders including cancer,
cardiovascular diseases and inflammatory diseases.&#160;&#160;The Company
coordinates an international clinical research and development program with
external collaborators, hospitals and universities.&#160;&#160;For more
information, visit <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.novogen.com</font>.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">About
Marshall Edwards, Inc:</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 3.6pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Marshall
Edwards, Inc. (NASDAQ: MSHL) is majority owned by Novogen&#160;&#160;It as a
specialist oncology company focused on the clinical development of novel
anti-cancer therapeutics derived from the flavonoid technology
platform.&#160;&#160;This platform has generated a number of novel anti-cancer
compounds characterised by broad ranging activity against a range of cancer cell
types with few side effects.&#160;&#160;The combination of anti-tumour cell
activity and low toxicity is believed to be a result of the ability of these
compounds to target an enzyme present on the surface of cancer cells, thereby
inhibiting the production of pro-survival proteins within the
cell.&#160;&#160;Marshall Edwards, Inc. has licensed rights from Novogen Limited
(NASDAQ: NVGN) to bring three oncology drugs &#8211; phenoxodiol, triphendiol and
NV-143 &#8211; to market globally.&#160;&#160;The Company's lead investigational drug,
phenoxodiol, is in a Phase III multinational multi-centred clinical trial for
patients with recurrent ovarian cancer.&#160;&#160;More information on the trial
can be found at <font style="DISPLAY: inline; TEXT-DECORATION: underline">http://www.OVATUREtrial.com</font>.</font></div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">Under
U.S. law, a new drug cannot be marketed until it has been investigated in
clinical trials and approved by the FDA as being safe and effective for the
intended use. Statements included in this press release that are not historical
in nature are "forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act of 1995. You
should be aware that our actual results could differ materially from those
contained in the forward-looking statements, which are based on management's
current expectations and are subject to a number of risks and uncertainties,
including, but not limited to, our failure to successfully commercialize our
product candidates; costs and delays in the development and/or FDA approval, or
the failure to obtain such approval, of our product candidates; uncertainties in
clinical trial results; our inability to maintain or enter into, and the risks
resulting from our dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization, marketing, sales
and distribution of any products; competitive factors; our inability to protect
our patents or proprietary rights and obtain necessary rights to third party
patents and intellectual property to operate our business; our inability to
operate our business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to gain market
acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice; and
one-time events. We do not intend to update any of these factors or to publicly
announce the results of any revisions to these forward-looking
statements.</font></div>
    </div>
  </body>
</html>



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>novogenletterhead.jpg
<DESCRIPTION>NOVOGEN LOGO
<TEXT>
begin 644 novogenletterhead.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!E`/P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`JM!<QRW=U`I^>%EW#ZJ"*LUYWJ?B>/PW\6UM[QQ'8ZE8PH
M[MP$D#N$8GTY(/U!/2FE<SJ34+-GHE%%%(T"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHK.UG7-/T"S6[U*8PP,XC#!"WS$$@8
M`/H:&[;CC%R=HJ[-&BL_1]<T[7[,W>FW`GA5RC':5(8=B#SW'YUH4)WV"47%
MVDK,**R;KQ)I=EKEOHT]P5OK@`QQ^6QR#G'.,=C6M233'*$HV;6X457O;ZUT
MZU>YO;B*W@3[TDC!0/SKDI_BIX7AE*+/<2C^\D#8_7%)RBMV73H5:GP1;.UK
MQ'XX6I77-*NC]V6V:/\`[Y;/_L]>I:+XOT/Q`_E6%\C3XSY,@*/^`/7\,UQW
MQKTXW'AJROU4DVESM8^BN,']0M:4I+F31QX^E*-*49*S10^&'Q#\[R/#VLS?
MO>$L[AS]_P!(V/KZ'OTZXSZY7Q_].#7T)\,?&;>)=(:QOI-VIV:@.Q/,T?0/
M]>Q]\'O6E6%M4<N"Q/-^[GOT.\HHK+UOQ%I?AV"*;5+GR4E8JF$9B3C/0`U@
MVEJSTXQE-\L5=FI138W$D:N`0&`(##!_$=JY_6/''A[0YF@N[]6N%.&BA4R,
MOUQP/H:&TM6.%.<WRP5V=%17&6OQ2\+W,H1KF>#)QNEA('YC.*Z^WN(;J!)[
M>:.:%QE)(V#*P]B*2DGLRJE&I3^.+1)114%Y>VNGVS7-Y<16\"?>DE8*!^)J
MC-)MV1/17%W'Q2\+P2%%N9Y@#C='`V/UQ5O3_B)X8U&80IJ(AD8X`N$,8/XG
MC]:CVD>YN\)72NX/[CJ:**YS4_'7A[1]1FL+V]:.YAQO40NV,@$<@8Z$53:6
MYE"G.H[05WY'1T5R/_"S/"G_`$$7_P#`>3_XFMO1/$&F^(;>6?3)S-'$^QR4
M9<'`/<#L:2G%Z)ESP]6"YI1:7H:=%8>M^+M%\/7,=OJ=TT,LB>8H$3-D9QV!
M]*U[:YAO+6*YMY%D@E0/&Z]&4C(-.Z;L0Z<XQ4FM&2T45D:9XGTG5]2NM/LK
MDR7-J6$J&-EVX;:>2,'FBZ0E"4DVEL:]%%%,D*X'XN_\BA!_U^I_Z"]=]7`_
M%W_D4(/^OU/_`$%ZBK\#.O`_[S#U.1\-7T_@37=.DN7/]D:Q:0RL[=%W*#GZ
MJQ(/^R<^E>V=1D5PUQX:3Q/\+]*M5"B[CL89+9SV<1CC/H1P?S[5'\,_$KZA
MIKZ)?%EO]/&T!^&:,''/NI^4_A44_=?+T9T8M*O%UE\479_HS,\3?\EGT'_K
ME%_Z%)7ILLJ00O+*P2-%+,QZ`#DFO,O$W_)9]!_ZY1?^A25UOCV=[?P-JSH2
M"8?+X]&8*?T)IQ=N9DUX<_L8=TE^)YU;QW_Q4\5R/-+)!H]H<A1_`AZ`#IO;
M!))Z<^@%>G67A'P_I]L((-(M"H')DB$C-]6;)-8'PHMHX?!@F4#?<7$CN?H=
MH_1:[FBG%6YGNQ8VO)5'2AI&.ECS3QI\.[9+1]7\/Q&UN[;]ZT$1(#`<Y3^Z
MPZC'7ZU/H.I'XA^`-2TF\93J"1>4SG@,>L<GYKS[J?6O1*\D\`QC3OB=K>GP
M\0!9U`]`L@V_D"12:Y)IKJ.,OK.&G"IJXZI^75'CDL4D$KPS(4EC8HZ,,%6!
MP0?QK6\+:[)X;\266IH3LC?$RC^*,\,/RY'N!7<?%WP>]CJ!\1646;2Y(%T%
M'^KEZ!OHW\_K7E]>DFI(^,J0E0J6['U\CK)&LB,&1@"K`\$'O7F'B,?\)5\5
M=.T8?/::<`\P[9X=OSPBUN^`M>CE^&=K?W3Y%A`\<I]!%D#_`,="UE_"NSEO
M&U;Q+=C]_>SLBGVSN?'MD@?\!KSZJ]Y0/K<#*U*6(\K+U?\`DBS\3/%EQH]I
M#I.G.R7UXN6=/O1QYQ\O^TQR`?8]\&E\(_#73]-LX[G6+>.[U!QN9)/FCB]@
M.A/J3GGI6%?QC4?CM!!/S'"Z%1_N0^8/_'J];J8KGDY/H;UIO#T84J>G,KM^
MI@ZGX+\/:K;&&;2[>,X^62!!&Z^X(_D<BO.=+N[_`.&OC$:3>3F72;E@=Q^[
MM8X$@'8@C##T'T->R5YI\9+6-]&TVZ(_>)<-$#_LLI)_]!%%6-ES+="P-9SG
M["H[QE^'FCT>XN(K6VEN)W"11(7=CV4#)/Y5X_8VVH?%3Q'+=7LLEOHUHV%C
M0_=!Z*.V\CDMV_*NI\57\Q^$0N"Q,MQ:6X=NA.\H&_/)_.KGPRMH[?P)9.@&
MZ=Y)7/J=Y'\E`_"B7OR4>FXZ/^ST)55\5^5>7<U+/P?X=L81'#HUF0!C=)$)
M&/U+9)JI?_#_`,,Z@Z.VF1P.KALV_P"[#8.<$#@@]#Q^5=-2,RK]Y@/J:TY(
M[6.-8BJGS*3OZB@8&!TKRAK&TU'XX7UM>VT5Q`8P3'*H921"F.#7J]>-:QK+
MZ#\8-0OX[*2\9451#&<$YA3GH>GTJ*ME:_<ZLO4I2J*._*_T/2O^$/\`#?\`
MT`M/_P#`=?\`"M#3]+L-*B>/3[."U1VW,L*!03C&3BN!_P"%J7G_`$*=]_WV
MW_Q%>@:==&^TRTO&B:%IX4E,3=4+`'!^F<547!_"8UZ>(IK][L_._P"IY?\`
M$NS74?'>A6+N46YC2(N!DJ&D(S^M7/ASK%QI&IW7@[53LF@=C;9[]V4>Q'SC
MV)]JC\=_\E-\,?[T/_HZKOQ-\/RM##XFTW,=]8$&5DZE`<AOJI_0GTK&S4G)
M=#T5*,Z-.A/:2T\G?0]$KRKX=?\`)0O$G^]-_P"CC7=^%?$$/B708+^/"R_<
MGC'\$@ZCZ=Q[$5PGPZ_Y*%XD_P!Z;_T<:N33<6CEH0E"E6C+=)?F>JT445L>
M<%<#\7?^10@_Z_4_]!>N^KC?B9I5_J_AF&WT^UDN9A=HY1,9"A6&>?J*BI\+
M.K!-1Q$&^YM>$_\`D3]%_P"O&'_T`5PGCW3+GPQXCM?&&E)\ID`N4'`W].?9
MAP??!ZFO0/#EO-:>&-*MKB,QS16D22(W56"`$5:U&PM]4TZ>QNTWP3H4<>Q[
MCW'44G'FC8JG7]E7<MT[W\T>6ZEJ5OJ_Q3\,ZA:-N@N+>)USU'S29!]P<@_2
MO1_$>FMK'AS4-/3_`%D\#*G./FQE?U`KR30_">M:/\0+&.:QNI;:UNL"Z6)C
M&4P2&ST'7\#FO;ZFE=IW-\<XTY4_9N]EI]YYC\(];3[)=:#<-LN(I#-$C<$J
M<!E^H(S^/M7IU>>>+_A_<W6I_P!N^')A;ZB&\QXMVS>W]Y3V8]P>#[<YI1>-
MO&^GH;>_\*RW,ZC`E2%P"?4[05/X8HC)P7+(*U&.*E[6BU=[INS3/1-5U.VT
M?2[C4+MML,"%F]3Z`>Y.`/K7FOPHM+B_UG5_$-PN/,)C!QP7=M[X^GR_G44N
MA^,_'MU$VLK_`&9IR-N$97;CW"$Y+>[8QSCTKT[2=*M-%TR#3[*/9!"N!DY)
M/<D]R3S0KSDGT1,N3#494T[SEO;HB>ZM8+ZTEM;J))8)5*21N,A@>H-?.WCW
MP)<>$;[SH-TNDSMB&4\F,_W&]_0]_P`Z^CZJZCIUKJVG3V%[$LMM.A1T/IZ^
MQ'4'L173";BSQL1AXUHVZGSYHFOO;_#S4="B.9[N_3:@/)0J,X_%%'_`C7O7
MA[2ET3P_8Z:N"8(@KD?Q/U8_B237D7A'P+>:?\3'LKJ&5K/3W^T+.4(64#F/
MGIG)4D>Q%>X5$E^\<CJHSM@J=+KJWZW:7X(\B\=>;X:^)&G^(0C&"78[%>Y4
M;'7Z[,?G7K%M<0WEM%<V\BR0RJ'1UZ,IY!K/\0Z!9^)-)DL+P$`G='(OWHW'
M1A_GD$UYS:6GCKP$SV]G:C5=-W$JJ*9`,]PH.Y3ZCD?7K6.L)-]&>A[N*I1C
M=*<=->J/6Z\D^*>I'6-:T_PW8'S9D<%P#QYK\*OX`DG_`'JLW/B[QWK*&UTS
MPW-8LXP9GC;(^C.%4?CFMCP3X!.A7!U7595N=4?)&"66+=U.3RS')R?<_4DF
MZGNQV*HTXX1^UJM<RV2=]?,V]>T#[;X)N-$M^66V6.'/=D`*_JHKD_A-K\3Z
M=+H$[;+F!VDA5N"R$Y8?4-G/U]C7I=>>>+_AY+?:@=;\/S_9M1W>8\>[8';^
M\K#[K?H?;G+G%IJ43+#U83A*A5=D]4^S/0Z\T^,P!T/3<_\`/RW_`*`:JP>+
M_'VD@6VH>'9+QDX\P6[Y;_@294_@*S]=_P"$T\>106TGATVD,,A=2ZM%R1CD
MN1D8]!4SFI1:2U-\+A94:T:DY+E76Z/7K/\`X\;?_KFO\J\WM/\`DO%[_P!<
MO_:*5Z7;HT5M%&V-RH%./4"O+M9L/$^G_$F^UW2-&:[0JJQL^-C`Q*I_B!Z@
MU539>IA@K.5172O%K7Y'JM%><?\`"3_$3_H5;?\`(_\`Q==+X4U/Q#J*79U_
M2X[`H5\D)_&#G/\`$>G'YU2FF[&-3"RIQYFU\FCD/'?_`"4WPQ_O0_\`HZO3
MW19$9'4,C##*PR"/0UP'C#1-3O\`Q]X?OK2RDFM;=HC+*N,)B7)SSZ<UZ#2@
MO>D:8F2=*DD]E^IY%:._PU\?-:RLPT34>58]$7/!^J$X/^R<^E6/AUQ\0O$O
M^]-_Z.-=EXU\-)XG\/R6R!1>1?O+9SV<?PY]"./R/:N,^%FD:KI^O7\VH:?>
M6RO;X#SQ,H9MP/4]36?*XS2Z'8JT*N&G-OW[)/SMLSU:BBBN@\8****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**IPZI:7-Z;2!Y)7",QD2
M)VB&URC+YH&S>&!!3.X8/%7*`"BBL_1-;T[Q'H\&K:3<?:+&?=Y<NQDW;6*G
MA@".01R*`-"BBB@`HHHH`**IWFJ6EC<6MO,\AGNGVQ1Q1/(QY`+$*"50%E!<
MX5=PR1D5<H`**S]*UO3M;^V_V=<>=]ANY+*X^1EV3)C<O(&<9'(R/>M"@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`KD_'>F:UJMOH<&C27:(NL6[Z@;6[-N
MWV3#"3+!E)'(X!STQTKK**`/"_"WA7XH1WNGCQ%J6LBW#QAO(O5E*PEY1+'*
MWVA,$JX;S%61U&S:5*;:Z#P[H'C>+6-%GU>;4GLYGMWO(GU(YM3;6AC^8*YW
MB:=MY"DC"*7R6(7U2B@#PM[WQ7=?%:;3=/UZ2>[:XU1D:"_$UK!$+=5MEEA4
MD1F.4X;?&,L>KFJ\7A/XH.;5)+WQ!Y0LKEI8VU%8@EU]FVQ[9%NG>0&55/S;
M5!)(50S`>^44`?/DWA7XP_V-,C:EK+:DR(B_9[V/RWCVQ':TC7"E'4HP+)'E
MCNR[A\CL_$FF>-;KQIIL&D65];Z%:2VUO+=IJK$W-L0PG+!IP0P#@!MC2$KN
M$@(45ZA10!\\>'_!/Q*TB/2+6"WU6TTRVB4:E:1:LB_:?]++N(-LN(V,97D&
M/[KC/S?-IZCX5^*D^CVZM?:E)?PZ%'&K6VJ^4/M?VO.&PZAG%N2"QR"1]YC@
MU[I10!XW\19O%=S\26TWPO/J37B:%%=VT%O>"*))5N\-(Z,ZHX*!EP0V=PXP
M,C#T'PC\1?#6GZ=9VVE7TMK+IYANX%UC:EM,;QG,B(MPF6\I5&$=`=YR>6!^
M@**`/"WT#XLR:9:3F;4AJ=IHZ)&%U)`K7:WN1O4/LD/V;J7!#=\M5B]T/XEV
M%^)]/MM2U""&]U*&*VEULHKVCH!;,Y\T,Q5GD8$GS/E`W+A"/;**`/'_``CH
M_P`0K?Q-#+XF35;C1(I9ELX(=15'@)EC9))\3EI(]N\;6DF(P1@C!.7;Z!\5
M;34M.N;F[UF\,6IQS:A#!=0K!<1)*[%HV:X!PRL!Y8CB0C;D97)]THH`^?-+
M\"_$BV\6^$=8G74C+&D4>KW$FK!V*"[=F0YD)9/*\L[5R#Z9S6W=Z5\15\+G
M35TW5;G6YI;A[S5EUG;&6!E\DV\:W$>U3O7(*JH"C,;D`#VBB@#P?3?#'Q'L
M/!L^;*^.NW&MSZA-;PWL4,-P'CC4F5XIHW7YB[*$;&5PRX*D>\444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
5%%`!1110`4444`%%%%`!1110!__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
